On August 13th, Remegen (688331.SH/09995.HK) announced that its global first-in-class BLyS (BAFF)/APRIL dual-target fusion ...

The China-based phase 3 trial of telitacicept in primary Sjögren's syndrome (pSS) met its primary endpoint, which focused on ...

Phase 3 results position telitacicept as potential best-in-disease profile in primary Sjögren's disease Telitacicept ...

While Vor provided no details on the results, the company is now evaluating a global trial of the drug in the chronic immune ...

Novartis may have abandoned one Sjögren's syndrome asset this year, but it looks like the drugmaker has a winner on its hands ...

Vor Bio shares climb as RemeGen's Phase 3 study in China shows telitacicept improves disease activity in primary Sjögren's ...

Good news in research for Novartis. The pharmaceutical giant has achieved the hoped-for results for Ianalumab, a candidate ...

Venus Williams is back on the professional tennis tour at age 45 and will be returning to the U.S. Open next week for her ...

Ianalumab is a fully human monoclonal antibody designed to deplete B cells via antibody-dependent cellular toxicity and inhibit BAFF-R-mediated signals of B cell function and survival.

Adults with Sjögren’s disease complicated by a subtype of cutaneous vasculitis are more likely to develop non-Hodgkin’s ...

Novartis today announced positive top-line results from its Phase III trials evaluating ianalumab (VAY736) in adults with active Sjögren's disease. Both trials met the primary endpoint of ...